178 related articles for article (PubMed ID: 34465864)
41. SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
Wang F; Li Z; Zhou J; Wang G; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Aug; 40(1):259. PubMed ID: 34407842
[TBL] [Abstract][Full Text] [Related]
42. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
[No Abstract] [Full Text] [Related]
43. The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone.
Xiang J; Wang G; Xia T; Chen Z
Biomed Pharmacother; 2019 Jan; 109():2210-2217. PubMed ID: 30551478
[TBL] [Abstract][Full Text] [Related]
44. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
45. Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.
Tan Q; Brunetti L; Rousseaux MWC; Lu HC; Wan YW; Revelli JP; Liu Z; Goodell MA; Zoghbi HY
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1511-E1519. PubMed ID: 29382756
[TBL] [Abstract][Full Text] [Related]
46. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.
Rivera-Munoz P; Laurent AP; Siret A; Lopez CK; Ignacimouttou C; Cornejo MG; Bawa O; Rameau P; Bernard OA; Dessen P; Gilliland GD; Mercher T; Malinge S
Blood Adv; 2018 Jul; 2(13):1616-1627. PubMed ID: 29986854
[TBL] [Abstract][Full Text] [Related]
47. JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia.
de Bock CE; Cools J
Mol Cell Oncol; 2018; 5(3):e1458014. PubMed ID: 30250904
[TBL] [Abstract][Full Text] [Related]
48. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
49. JAK3: a two-faced player in hematological disorders.
Cornejo MG; Boggon TJ; Mercher T
Int J Biochem Cell Biol; 2009 Dec; 41(12):2376-9. PubMed ID: 19747563
[TBL] [Abstract][Full Text] [Related]
50. HiJAKing T-ALL.
Asnafi V
Blood; 2014 Nov; 124(20):3038-40. PubMed ID: 25395141
[TBL] [Abstract][Full Text] [Related]
51. PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway.
Hou S; Wang X; Guo T; Lan Y; Yuan S; Yang S; Zhao F; Fang A; Liu N; Yang W; Chu Y; Jiang E; Cheng T; Sun X; Yuan W
Leukemia; 2023 Aug; 37(8):1626-1637. PubMed ID: 37393343
[TBL] [Abstract][Full Text] [Related]
52. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
53. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
54. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
55. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
56. Somatic inactivation of ATM in hematopoietic cells predisposes mice to cyclin D3 dependent T cell acute lymphoblastic leukemia.
Ehrlich LA; Yang-Iott K; DeMicco A; Bassing CH
Cell Cycle; 2015; 14(3):388-98. PubMed ID: 25659036
[TBL] [Abstract][Full Text] [Related]
57. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
Nairismägi M-; Gerritsen ME; Li ZM; Wijaya GC; Chia BKH; Laurensia Y; Lim JQ; Yeoh KW; Yao XS; Pang WL; Bisconte A; Hill RJ; Bradshaw JM; Huang D; Song TLL; Ng CCY; Rajasegaran V; Tang T; Tang QQ; Xia XJ; Kang TB; Teh BT; Lim ST; Ong CK; Tan J
Leukemia; 2018 May; 32(5):1147-1156. PubMed ID: 29434279
[TBL] [Abstract][Full Text] [Related]
58. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
59. LIF-dependent JAK3 activation is not essential for retinal degeneration.
Lange C; Thiersch M; Samardzija M; Bürgi S; Joly S; Grimm C
J Neurochem; 2010 Jun; 113(5):1210-20. PubMed ID: 20345762
[TBL] [Abstract][Full Text] [Related]
60. Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.
Warsi J; Hosseinzadeh Z; Dong L; Pakladok T; Umbach AT; Bhavsar SK; Shumilina E; Lang F
J Membr Biol; 2013 Dec; 246(12):885-92. PubMed ID: 23934551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
